Arora Mili, Wun Ted
Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California.
Semin Thromb Hemost. 2014 Apr;40(3):313-8. doi: 10.1055/s-0034-1370769. Epub 2014 Mar 5.
Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
静脉血栓栓塞症（VTE）是恶性肿瘤常见的并发症。这与潜在的癌症及各种治疗的血栓形成作用有关。与无恶性肿瘤患者的VTE相比，癌症相关血栓形成在接受抗凝治疗时与死亡率增加、复发及出血相关。这些更差的结局归因于潜在癌症、宿主反应、抗肿瘤治疗以及抗凝剂与癌症药物之间相互作用的复杂交互。VTE的一级预防可能降低发病率，甚至可能改善癌症相关生存率，但迄今为止的研究尚未明确确定可能最受益的患者群体，也未始终表明抗凝治疗对生存有益。
